{"id":"W4379383902","doi":"10.1177/17588359231175440","title":"Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency; Ottawa Hospital; Sinai Health System; University of Toronto; University of Alberta; University of Calgary","funders":"National Cancer Institute; Mylan; AstraZeneca Canada; Seagen; Gilead Sciences; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Trastuzumab; Oncology; Breast cancer; Metastatic breast cancer; Internal medicine; Clinical trial; Biomarker; Disease; Hormone receptor; Pertuzumab; Cancer; Population; Human Epidermal Growth Factor Receptor 2","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002904213,0.0007944117,0.004872832,0.000821982,0.00007898566,0.00002331392,0.0007625967,0.0008093033,0.002724926],"category_scores_gemma":[0.0004856364,0.0005733558,0.0003494075,0.001678409,0.0006535845,0.0002050067,0.0001562882,0.002269163,0.0001810645],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.006529665,"about_ca_system_score_gemma":0.008106926,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009310761,"about_ca_topic_score_gemma":0.003384941,"domain_scores_codex":[0.9917804,0.002156396,0.001973627,0.00120412,0.001370319,0.001515162],"domain_scores_gemma":[0.9952343,0.002778296,0.0004622975,0.0006966321,0.00008077401,0.0007477289],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000138863,0.0009627937,0.0003088561,0.01113775,0.0002778851,0.003336247,0.0003482132,0.00003074787,3.891265e-7,0.000109322,0.00004326437,0.9833057],"study_design_scores_gemma":[0.002587075,0.001460246,0.00008755859,0.0261721,0.0005596871,0.0006192231,0.0002536599,0.001261076,3.102323e-7,0.0006816033,0.9658419,0.0004755306],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00003983862,0.9937808,0.00008090686,0.001874291,0.0009420016,0.002541334,0.00007117543,0.0001388989,0.0005307395],"genre_scores_gemma":[0.0001460247,0.9943541,0.000456205,0.0006221038,0.0008927659,0.002917819,0.0001564016,0.0002133401,0.0002412226],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9828301,"threshold_uncertainty_score":0.9996718,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1399657081691481,"score_gpt":0.5367814479793399,"score_spread":0.3968157398101919,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}